Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Multiple Myeloma × Olanzapine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vomiting 5 Nausea 5 Neoplasms 4 Hematologic Neoplasms 4 Anorexia 3 Breast Neoplasms 2 Testicular Neoplasms 1 Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1 Prosthesis Failure 1 Opioid-Related Disorders 1 Nutrition Disorders 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Gynecologic Cancer 1 Cachexia 1 Advanced Cancer 1

Interventions

Dexamethasone 142 Bortezomib 79 Lenalidomide 78 Thalidomide 39 Melphalan 37 daratumumab 36 pomalidomide 32 Cyclophosphamide 29 carfilzomib 23 Calcium Dobesilate 23 Prednisone 18 Doxorubicin 13 elotuzumab 11 Filgrastim 11 ixazomib 10 Peripheral Blood Stem Cell Transplantation 10 isatuximab 9 Vincristine 9 belantamab mafodotin 8 Zoledronic Acid 8 dexamethasone acetate 7 Granulocyte Colony-Stimulating Factor 7 Epoetin Alfa 7 selinexor 5 Carmustine 5 fludarabine 4 Radiotherapy 4 Interferon-alpha 4 Etoposide 4 Denosumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06588413 2024-11-22

FONDO-LOW

Augusta University

Phase 3 Recruiting

Multiple Myeloma, Nausea

Data powered by HemOnc (CC BY 4.0) Colophon ⚡